Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2021 | Buy → Neutral | HC Wainwright & Co. |
Highlights Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available molecular diagnostic test, helping avoid repeat FNAsLarge real-world analysis (n=28,144) demonstrates how ThyGeNEXT® + ThyraMIR®v2 refines risk in Bethesda III/IV nodules, especially in RAS-like and mutation-negative casesPresentations were held during the ATA Annual Meeting, September 10–14, 2025, at the Westin Kierland in Scottsdale, Arizona PARSIPPANY, NJ, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) presented two new scientific pos
●Q2 Revenue of $9.2 million ●Q2 Cash Collections of $10.8 million ●Q2 Thyroid test volume up 16% year-over-year to record levels ●Q2 Thyroid revenue of $8.7M; up 25% year-over-year to record levels PARSIPPANY, NJ, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the second quarter ended June 30, 2025 and provided a business and financial update. Second quarter Net Revenue was $9.2 million. Loss from continuing operations in the second quarter of 2025 was $0.5 million. "The Company achieved record Thyroid test volume, revenue, cash collections in the second quarter of 2025 driven by increased vo
●Q1 Revenue of $11.5 million; a 13% increase year-over-year ●Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ●Q1 Thyroid test volume up 16% year-over-year to record levels ●Q1 Thyroid revenue of $8.0M; up 19% year-over-year to record levels ●Initiates Full Year 2025 Revenue Guidance of approximately $38 million PARSIPPANY, NJ, May 08, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the first quarter ended March 31, 2025 and provided a business and financial update. First quarter Net Revenue was $11.5 million. Income from continuing operations in the first quarter
8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
10-Q - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
10-Q - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
HC Wainwright & Co. downgraded Interpace Biosciences from Buy to Neutral
HC Wainwright & Co. reiterated coverage of Interpace Biosciences with a rating of Buy and set a new price target of $9.00 from $6.00 previously
HC Wainwright resumed coverage of Interpace Biosciences with a rating of Buy and set a new price target of $6.00 from $10.00 previously
●2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year ●2021 Full Year Net Loss Improved $11.5 Million vs Prior Year ●Full year Cash Collections improved by 31% to $43.1 million and outpaced Revenue by nearly $2 million PARSIPPANY, NJ, March 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal year and fourth quarter ended December 31, 2021 and provided a business and financial update. "2021 has been a transformative year for Interpace," said Thomas Burnell, President and CEO. Burnell added, "The Company e
PARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (OTCQX:IDXG) ("Interpace") a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal, Ph.D., has been appointed to the Interpace Board of Directors effective February 1, 2022. Dr. Aggarwal replaces Eric B. Lev, both designees of Ampersand 2018 Limited Partnership, a Series B Preferred stockholder of the Company. Dr. Aggarwal has over thirty years of experience in both pharmaceutical services and clinical diagnostics. In addition to serving as Managing Partner of The Channel Group, Dr. Aggarwal provides strategic advisory services to companies with operations or investments in
●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quarter Net Revenue was $10.4 million, a 6% increase as compared to the same period of 2021. Our Net Loss in the first quarter of 2022 was $2.2 million, which represents an improvement of approximately $2 million from the prior year first quarter, driven by higher Net Revenues and lower oper
●Q3 Revenue of $9.5 Million is a 15% Improvement versus Q3 2020 ●Year to Date Revenue of $30.5 Million Up 34% Versus Prior Year ●Second Consecutive Record Cash Collection Quarter ●Significantly Improved Liquidity with Comerica Bank $7.5 Credit Facility ●Entered into $8 million term loan with BroadOak Fund, V, L.P. ●Announcing New Proposed $30 Million Rights Offering PARSIPPANY, NJ, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal quarter ended September 30, 2021 and provided a business and financial update. "2021 has been a dynamic and meaningful year in the evolution of Interpace
●Q2 Revenue of $11.2 Million Surpasses Q1 2021 as Company's Highest Revenue Quarter ●Company approaching EBITDA breakeven on Higher Clinical Volume, Revenue, Improved Gross Profit and Operating Expense Containment ●Restructuring Exceeding Full-Year Savings Expectations ●On Track to Exceed Full Year 2021 Revenue Growth of 35% ●Q2 Cash Collections in Excess of $11 Million Representing Highest Collection Quarter PARSIPPANY, NJ, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal quarter ended June 30, 2021 and provided a business and financial update. "Followin
SC 13D/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)
SC 13D/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)
SC 13G/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)